Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

NCT01392547 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Congenital Bleeding Disorder
Haemophilia A With Inhibitors
Haemophilia B With Inhibitors

Interventions

DRUG: vatreptacog alfa (activated)
DRUG: eptacog alfa (activated)

Sponsor

Novo Nordisk A/S